Literature DB >> 19734431

Second bone marrow transplantation for patients with thalassemia: risks and benefits.

Polina Stepensky, Reuven Or, Michael Y Shapira, Shoshana Revel-Vilk, Jerry Stein, Igor B Resnick.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19734431      PMCID： PMC2738733          DOI： 10.3324/haematol.2009.006817

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

Review 1.  Beta-thalassemia.

Authors:  Deborah Rund; Eliezer Rachmilewitz
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

Review 2.  Allogeneic stem cell transplantation for thalassemia major.

Authors:  Emanuele Angelucci; Donatella Baronciani
Journal:  Haematologica       Date:  2008-12       Impact factor: 9.941

3.  Second marrow transplants for graft failure in patients with thalassemia.

Authors:  D Gaziev; P Polchi; G Lucarelli; M Galimberti; P Sodani; E Angelucci; C Giardini; D Baronciani; B Erer
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

4.  Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

Authors:  D K L Cheuk; A S P Mok; A C W Lee; A K S Chiang; S Y Ha; Y L Lau; G C F Chan
Journal:  Bone Marrow Transplant       Date:  2008-06-16       Impact factor: 5.483

5.  Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.

Authors:  David A Jacobsohn; Reggie Duerst; William Tse; Morris Kletzel
Journal:  Lancet       Date:  2004 Jul 10-16       Impact factor: 79.321

6.  Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.

Authors:  Robert Iannone; James F Casella; Ephraim J Fuchs; Allen R Chen; Richard J Jones; Ann Woolfrey; Michael Amylon; Keith M Sullivan; Rainer F Storb; Mark C Walters
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

7.  Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft.

Authors:  J Gaziev; P Sodani; G Lucarelli; P Polchi; S Marktel; K Paciaroni; M Marziali; A Isgrò; M D Simone; A Roveda; A Montuoro; A Lanti; C Alfieri; G De Angelis; C Gallucci; F Ciceri; M G Roncarolo
Journal:  Bone Marrow Transplant       Date:  2008-06-23       Impact factor: 5.483

8.  Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.

Authors:  I B Resnick; M Aker; P Tsirigotis; M Y Shapira; A Abdul-Hai; M Bitan; B Gesundheit; A Amar; A Ackerstein; S Samuel; S Slavin; R Or
Journal:  Bone Marrow Transplant       Date:  2007-09-10       Impact factor: 5.483
  8 in total
  2 in total

1.  Second BMT for thalassemia major using CY post transplant.

Authors:  N Yaqub; S Khalid; F Itrat; A Khan; S K Gilani; M E Missiry; M H Hussain; C Uderzo; L Faulkner
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

2.  HLA-matched sibling bone marrow transplantation for β-thalassemia major.

Authors:  Mitchell Sabloff; Mammen Chandy; Zhiwei Wang; Brent R Logan; Ardeshir Ghavamzadeh; Chi-Kong Li; Syed Mohammad Irfan; Christopher N Bredeson; Morton J Cowan; Robert Peter Gale; Gregory A Hale; John Horan; Suradej Hongeng; Mary Eapen; Mark C Walters
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.